Antigen News and Research RSS Feed - Antigen News and Research

New research may explain why people with blood group O get more severely ill from cholera

New research may explain why people with blood group O get more severely ill from cholera

People with blood type O often get more severely ill from cholera than people of other blood types. New research from Washington University School of Medicine in St. Louis may explain why. [More]
Leading Chikungunya vaccine in clinical trial phase 2

Leading Chikungunya vaccine in clinical trial phase 2

With the first patient vaccinated, a Phase 2 clinical trial of a promising prophylactic vaccine candidate against Chikungunya fever has now commenced. The product is the most advanced Chikungunya vaccine candidate globally and is developed by the Austrian biotech company Themis Bioscience GmbH. [More]
Fiocruz to start phase II clinical trials of novel vaccine for schistosomiasis

Fiocruz to start phase II clinical trials of novel vaccine for schistosomiasis

The Oswaldo Cruz Foundation at Rio de Janeiro, Brazil, will start the phase II clinical trials of a vaccine for schistosomiasis, called 'Sm14 Vaccine'. [More]
Naturally-occurring sugars in woman's breast milk may protect infants against life threatening bacteria

Naturally-occurring sugars in woman's breast milk may protect infants against life threatening bacteria

A type of sugar found naturally in some women's breast milk may protect newborn babies from infection with a potentially life threatening bacterium called Group B streptococcus, according to a new study from Imperial College London. [More]
Research findings could lead to new ways of preventing or treating organ transplant rejection

Research findings could lead to new ways of preventing or treating organ transplant rejection

An international team led by researchers from the University of Pittsburgh School of Medicine found that targeting certain donor cells lowered the risk of organ rejection in mice that underwent kidney and heart transplants. [More]
Interpace Diagnostics introduces new AccuCEA Insights for diagnosing and treating pancreatic cancer

Interpace Diagnostics introduces new AccuCEA Insights for diagnosing and treating pancreatic cancer

Interpace Diagnostics Group, a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management, reported today that the Company has launched a new version of their AccuCEA™ product called "Insights" for Gastroenterologists who focus on diagnosing and treating pancreatic cancer. [More]
Study demonstrates safety and effectiveness of new SLN radiotracer in breast cancer patients

Study demonstrates safety and effectiveness of new SLN radiotracer in breast cancer patients

Determining whether breast cancer has spread to sentinel lymph nodes (SLN) is key to prognosis and treatment, making SLN mapping critical. [More]
Novartis Prizes for Immunology to be awarded to six scientists for groundbreaking research

Novartis Prizes for Immunology to be awarded to six scientists for groundbreaking research

Today Novartis announced that six scientists will receive the 2016 Novartis Prizes for Immunology at the upcoming 16th International Congress of Immunology in Melbourne, Australia on Aug 22, 2016. [More]
FDA grants Orphan Drug Designation to CD4CAR therapy for treatment of peripheral T-cell lymphoma

FDA grants Orphan Drug Designation to CD4CAR therapy for treatment of peripheral T-cell lymphoma

iCell Gene Therapeutics today (Aug. 11) announced that the Food and Drug Administration has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL). [More]
Antioxidant compound could be effective to combat immune rejection after islet transplantation

Antioxidant compound could be effective to combat immune rejection after islet transplantation

A team of researchers has found that doses of bilirubin help provide suppression of the immune response following islet transplantation in mouse models. [More]
Analysis of biopsies during early treatment predicts patient’s response to melanoma immunotherapy

Analysis of biopsies during early treatment predicts patient’s response to melanoma immunotherapy

Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in the journal Cancer Discovery. [More]
Battling IBD with super heroes: an interview with Dr James Lindsay

Battling IBD with super heroes: an interview with Dr James Lindsay

Takeda Pharmaceutical Company Limited has launched IBD Unmasked as a first-of-its-kind global initiative designed to raise awareness of the unsung Super Heroes of the global IBD community. [More]
People with filariasis show two to three-fold increased risk for HIV

People with filariasis show two to three-fold increased risk for HIV

Since the start of the HIV epidemic, there have been speculations as to why HIV and the immunodeficiency syndrome it causes have spread so much more in Africa than in other countries around the world. [More]
Scientists engineer therapeutic system with two arms to get better hold on cancer target

Scientists engineer therapeutic system with two arms to get better hold on cancer target

Scientists have engineered a sort of biological barbell that can get inside cancer cells and do damage to two proteins that work independently and together to enable cancer's survival and spread. [More]
Preclinical data on Selecta’s novel immune tolerance platform published in Nature Nanotechnology

Preclinical data on Selecta’s novel immune tolerance platform published in Nature Nanotechnology

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, announced today that Nature Nanotechnology has published an article that presents preclinical results from Selecta’s research which demonstrate the broad potential applicability of Selecta’s novel immune tolerance platform. [More]
Researchers shed light on mechanism for inducing memory B cell differentiation

Researchers shed light on mechanism for inducing memory B cell differentiation

A group of researchers at Immunology Frontier Research Center (IFReC), Osaka University and RIKEN Center for Integrative Medical Sciences jointly clarified the mechanism for inducing germinal-center B cells' differentiation into memory B cells, immune cells that remember antigens, at the molecular level. [More]
Bio-Rad expands product line by launching two human recombinant antigens

Bio-Rad expands product line by launching two human recombinant antigens

Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products, today announced the launch of two human recombinant antigens, expanding the company's portfolio of Critical Raw Materials for the in vitro diagnostics market. [More]
Puritan wins two new U.S. patents to strengthen position in flocked swab technology

Puritan wins two new U.S. patents to strengthen position in flocked swab technology

Puritan Medical Products Co. LLC, an American manufacturer of single¬-use medical, diagnostic, forensic and critical environment products for the global market, was awarded two U.S. patents for their HydraFlock and PurFlock Ultra swabs, issued March 1 and 8, respectively. [More]
VALIDATE D-Dimer kit from LGC Maine Standards receives US FDA approval for use on hemostasis test systems

VALIDATE D-Dimer kit from LGC Maine Standards receives US FDA approval for use on hemostasis test systems

LGC Maine Standards is pleased to announce our VALIDATE D-Dimer calibration verification / linearity test kit has received US FDA 510(k) clearance for use on Instrument Laboratory ACL TOP hemostasis test systems. [More]
Management of prostate cancer varies by race

Management of prostate cancer varies by race

A study published in The Journal of Urology® indicates that treatment for low-risk prostate cancer, rather than watchful waiting, is most likely to be sought by black men. [More]
Advertisement
Advertisement